health - "cancer"

Breast cancer recurrence risk exists even when patients have remained disease free five years after cure. However, this risk is not too high, and women are advised not to give up on their fight against breast cancer.read more

The Premier, David Bartlett, is sending staff from the Education Department into Hobart's Hazelwood School to talk to teachers about their health concerns.

New research has found that even after 5 years of systemic therapy, breast cancer patients still have a substantial risk of the disease recurring.

A drug 'combo' of chemotherapy and a treatment for brittle bones has a dramatic effect on breast cancer according to researchers in the UK.

In the August 11 online edition of the Journal of Internal medicine reports discovery of the first practical laboratory test to guide the use of new-generation drugs that kill cancer cells by cutting off their blood supply. The new test, called the Microvessel Vascular (MVV) assay, was developed by Larry Weisenthal, MD, PhD., a medical oncologist who operates a cancer testing laboratory in Huntington Beach, California. The test works by measuring drug effects upon endothelial cells which make up blood vessels.read more

The risk of patients treated for breast cancer seeing a recurrence of the disease within five years remains low, according to a new study by American scientists.

The risk of patients treated for breast cancer seeing a recurrence of the disease within five years remains low, according to a new study by American scientists.

Breast cancer patients and their physicians may make more informed, long-term treatment decisions using risk assessment strategies to help determine probability of recurrence, a research team led by scientists at The University of Texas M. D. Anderson cancer Center reported in the Aug. 12 online issue of the Journal of the National cancer Institute.

Today's online edition of theJournal of Internal Medicinereports discovery of the first practical laboratory test to guide the use of new-generation drugs that kill cancer cells by cutting off their blood supply. The new test, called the Microvessel Vascular (MVV) assay, was developed by Larry Weisenthal, MD, PhD.

Bavarian Nordic's US subsidiary, BN ImmunoTherapeutics has entered into a scientific partnership with the National cancer Institute (NCI) in the United States. Under the Cooperative Research and Development Agreement (CRADA) the NCI and Bavarian Nordic will jointly develop new immunotherapies for the treatment of prostate cancer. Under the CRADA, BN ImmunoTherapeutics has rights to exclusively license intellectual property that results from this collaboration.